Neuralink announced on November 11, 2026, in Fremont, California, that its visual cortical prosthesis, Blindsight, received Breakthrough Device Designation from the US Food and Drug Administration. The implant aims to restore functional sight to blind patients by stimulating the visual cortex directly, bypassing damaged ocular anatomy and optic nerves.
Technical white papers released from Neuralink’s Fremont research headquarters detailed the architecture. Glasses-mounted digital cameras capture video frames and transmit encrypted optical telemetry to an embedded sub-cranial neural processing unit. The microprocessor converts optical pixel matrices into patterned electrical pulse streams. Micro-actuators distribute micro-currents across thousands of biocompatible flexible electrode threads implanted into the primary visual cortex (area V1). Direct cortical activation stimulates phosphene light constellations across the subject’s perceptual field.
According to Bloomberg and Reuters, Neuralink Founder and Chief Technology Architect Elon Musk addressed clinical neuroscientists during a product announcement. Musk said Blindsight’s fundamental mission was enabling individuals with severe visual impairments, including congenital blindness, to perceive visual inputs. He said initial visual fidelity may resemble early low-resolution arcade graphics; as electrode counts scale past tens of thousands of channels, artificial perception could eventually surpass natural biological human vision. He said securing FDA Breakthrough Designation provides a collaborative regulatory path toward clinical trials.
Pre-clinical non-human primate research records confirmed chronic cortical stimulation sustained stable functional margins across two-year implantation windows without eliciting reactive neuroinflammation. Non-human subjects differentiated geometric phosphene patterns and spatial motion vectors. The FDA Center for Devices and Radiological Health operates the Breakthrough Devices Program to expedite clinical evaluation for innovative technologies treating irreversible debilitating conditions. Under the program, Neuralink engineers will interface directly with dedicated FDA reviewing panels through regular sprint reviews. Neuralink opened its patient registry portal to prospective clinical trial candidates with severe optic nerve damage.
